116 related articles for article (PubMed ID: 21325145)
1. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis.
Singh S; Loke YK; Furberg CD
Thorax; 2011 May; 66(5):383-8. PubMed ID: 21325145
[TBL] [Abstract][Full Text] [Related]
2. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
Lincoff AM; Wolski K; Nicholls SJ; Nissen SE
JAMA; 2007 Sep; 298(10):1180-8. PubMed ID: 17848652
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
Loke YK; Singh S; Furberg CD
CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.
Hernandez AV; Usmani A; Rajamanickam A; Moheet A
Am J Cardiovasc Drugs; 2011; 11(2):115-28. PubMed ID: 21294599
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Clar C; Ebrahim SH
Cochrane Database Syst Rev; 2007 Jul; 2007(3):CD006063. PubMed ID: 17636824
[TBL] [Abstract][Full Text] [Related]
9. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
Loke YK; Kwok CS; Singh S
BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
[TBL] [Abstract][Full Text] [Related]
10. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Lago RM; Singh PP; Nesto RW
Lancet; 2007 Sep; 370(9593):1129-36. PubMed ID: 17905165
[TBL] [Abstract][Full Text] [Related]
11. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
Colmers IN; Bowker SL; Majumdar SR; Johnson JA
CMAJ; 2012 Sep; 184(12):E675-83. PubMed ID: 22761478
[TBL] [Abstract][Full Text] [Related]
12. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
13. The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta-analysis of observational studies.
Hidayat K; Du X; Wu MJ; Shi BM
Obes Rev; 2019 Oct; 20(10):1494-1503. PubMed ID: 31250977
[TBL] [Abstract][Full Text] [Related]
14. Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones.
Webb DR; Davies MJ; Gray LJ; Abrams KR; Srinivasan B; Das S; Taub N; Lawrence I; Sutton S; Khunti K
Diabetes Obes Metab; 2010 Feb; 12(2):124-32. PubMed ID: 19922476
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
16. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
18. Cancer and bone fractures in observational follow-up of the RECORD study.
Jones NP; Curtis PS; Home PD
Acta Diabetol; 2015 Jun; 52(3):539-46. PubMed ID: 25524432
[TBL] [Abstract][Full Text] [Related]
19. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.
Mahady SE; Webster AC; Walker S; Sanyal A; George J
J Hepatol; 2011 Dec; 55(6):1383-90. PubMed ID: 21703200
[TBL] [Abstract][Full Text] [Related]
20. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
